Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

15.90USD
18 Aug 2017
Change (% chg)

$-0.15 (-0.93%)
Prev Close
$16.05
Open
$15.95
Day's High
$16.15
Day's Low
$15.88
Volume
83,333
Avg. Vol
128,691
52-wk High
$18.00
52-wk Low
$11.64

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $713.25
Shares Outstanding(Mil.): 44.86
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -0.23 -- --
ROI: -7.15 2.83 14.89
ROE: -8.07 5.09 16.13

BRIEF-Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​

* Vanda Pharmaceuticals Inc - ‍total net product sales were $42.1 million in Q2 of 2017​

Aug 02 2017

BRIEF-Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia

Jul 21 2017

BRIEF-Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc

* Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing Source text for Eikon: (http://bit.ly/2rwELbT) Further company coverage:

Jun 19 2017

BRIEF-Vanda and UCSF announce license agreement for CFTR activators and inhibitors

* Vanda and UCSF announce license agreement for CFTR activators and inhibitors

Mar 29 2017

Competitors

Earnings vs. Estimates